Investors

-- NASDAQ Bell Closing on May 8 --
-- Release of 1Q08 Financial Results/Conference Call on May 9 --
-- Annual Shareholders Meeting on May 14 --

BERKELEY HEIGHTS, NJ, April 28, 2008 – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) has announced certain corporate events that will take place during May 2008.

NASDAQ Bell Closing – Thursday, May 8

Spiro Rombotis, President and Chief Executive Officer, will preside over the NASDAQ closing bell ceremony on Thursday, May 8, 2008. Mr. Rombotis will be joined at the ceremony by members of Cyclacel’s leadership team and certain financial community professionals at the NASDAQ MarketSite in Times Square.

This event will be broadcast live, beginning at 4:00 p.m. Eastern Time and accessed by the NASDAQ website at www.nasdaq.com or by logging on to the Cyclacel website at www.cyclacel.com.

Release of 1Q08 Financial Results and Conference Call – Friday, May 9

Cyclacel will announce its first quarter 2008 financial results on Friday, May 9, 2008. The Company will host a conference call and webcast at 4:00 p.m. Eastern Time that day to review these results as well as Cyclacel’s clinical development programs.

Conference call information:
US/Canada call: (877) 493-9121 / international call: (973) 582-2750
US/Canada archive: (800) 642-1687 / international archive: (706) 645-9291
Code for live and archived conference call is 44188667

For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90 days and the audio replay for 7 days.

Annual Shareholders Meeting – Wednesday, May 14

Cyclacel will hold its annual shareholders meeting on Wednesday, May 14, 2008 at 10:00 a.m. Eastern Time. The meeting will be held at Cyclacel’s corporate headquarters, located at 200 Connell Drive, Suite 1500, Berkeley Heights, New Jersey. This meeting is open to all stockholders of record as of March 20, 2008.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three Cyclacel drugs are in clinical development. Sapacitabine (CYC682), an orally-available cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly and cutaneous T-cell lymphoma (CTCL). Seliciclib (CYC202), an orally-available CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. CYC116, an orally-available, Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Several additional programs are at an earlier stage. Cyclacel’s ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair™ Cream for radiation dermatitis, Numoisyn™ Liquid and Numoisyn™ Lozenges for xerostomia. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in oncology, hematology and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates.

Please visit www.cyclacel.com for additional information. Note: The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn™ and Xclair™ are trademarks of Sinclair Pharma plc.

Risk Factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2007, as supplemented by the interim quarterly reports, filed with the SEC.

Contacts for Cyclacel: